iBio, Inc.

iBio, Inc. is an AI-driven biotechnology company headquartered in San Diego, California, focused on developing next-generation precision antibody therapies. Its mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine, ultimately advancing human health by developing novel therapeutic candidates and enabling the efficient production of life-saving biologics.

The company leverages advanced computational biology, proprietary 3D modeling, and AI-driven platforms, including EngageTx, ShieldTx, StableHu, and AI epitope steering, to discover and optimize antibodies. iBio's pipeline is primarily in the preclinical stage, with a focus on cardiometabolic diseases, obesity, and cancer. Key therapeutic candidates include IBIO-600, an anti-myostatin antibody aimed at muscle preservation and improved body composition, and IBIO-610, an Activin E antibody designed for fat-selective weight loss.

iBio is led by Martin Brenner, DVM, Ph.D., as Chief Executive Officer and Chief Scientific Officer, with Felipe Duran serving as Chief Financial Officer. The company recently received regulatory clearance to initiate a Phase 1 clinical trial for IBIO-600 in Australia in April 2026 and reported preclinical data for IBIO-610 in March 2026. iBio has strategically pivoted its business, divesting its contract development and manufacturing organization (CDMO) to concentrate resources on its core antibody discovery and development efforts, aiming to address unmet medical needs in challenging disease areas.